0001493152-26-046663.txt : 20261013 0001493152-26-046663.hdr.sgml : 20261013 20261013060200 ACCESSION NUMBER: 0001493152-26-046663 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20261013 DATE AS OF CHANGE: 20261013 EFFECTIVENESS DATE: 20261013 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FibroBiologics, Inc. CENTRAL INDEX KEY: 0001958777 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 863329066 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-600820 FILM NUMBER: 261454276 BUSINESS ADDRESS: STREET 1: 9350 KIRBY DRIVE STREET 2: SUITE 300 CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: 281-671-5150 MAIL ADDRESS: STREET 1: 9350 KIRBY DRIVE STREET 2: SUITE 300 CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: FibroBiologics Inc. DATE OF NAME CHANGE: 20221216 D 1 primary_doc.xml X0708 D LIVE 0001958777 FibroBiologics, Inc. 9350 KIRBY DRIVE SUITE 300 HOUSTON TX TEXAS 77054 281-671-5150 DELAWARE FibroBiologics LLC Fibrobiologics, Inc. FibroBiologics Inc. Corporation true 2021 Pete O'Heeron 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Executive Officer Director Chief Executive Officer Richard C. Cilento 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Director Robert Hoffman 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Director Victoria Niklas 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Director Kathleen H. Rubins 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Director Leigh Steinberg 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Director Jason D. Davis 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Executive Officer Chief Financial Officer Ruben A. Garcia 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Executive Officer General Counsel Hamid Khoja 9350 Kirby Drive Suite 300 Houston TX TEXAS 77054 Executive Officer Chief Scientific Officer Pharmaceuticals Decline to Disclose 06b false 2026-10-07 false true true true true false 0 1200000 1200000 0 Includes a convertible debenture in the principal amount of $1,200,000 and 125,000 restricted shares. The debenture is convertible following an event of default at a fixed conversion rate of $0.78 per share. false 1 0 0 0 The issuer intends to use the net proceeds from this offering for working capital and general corporate purposes. false FibroBiologics, Inc. /s/ Ruben A. Garcia Ruben A. Garia General Counsel 2026-10-12